H.R. 2376 · 115th Congress
Drug Diversion and Counterfeit Crackdown Act of 2017
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
LanceSponsor3 cosponsors · 2 D, 1 R
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill makes it illegal except in cases of a drug shortage to import into the United States prescription drugs manufactured outside the United States and intended by the manufacturer or labeled to be marketed outside the United States.
What it does: CRS summary · Introduced in House · May 4, 2017
Drug Diversion and Counterfeit Crackdown Act of 2017
This bill makes it illegal except in cases of a drug shortage to import into the United States prescription drugs manufactured outside the United States and intended by the manufacturer or labeled to be marketed outside the United States.
The bill establishes a penalty for knowingly dispensing or selling a counterfeit drug.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Drug Diversion and Counterfeit Crackdown Act of 2017
Latest action (May 5, 2017): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: May 4, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.